Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
Public ClinicalTrials.gov record NCT02313909. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS), Comparing Rivaroxaban 15 mg Once Daily With Aspirin 100 mg
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified. These strokes are likely due to a blood clot and therefore, can be called embolic stroke of undetermined source. The abbreviation is ESUS. The study will compare 2 blood thinners. Patients will be randomly assigned to either Rivaroxaban 15 mg or Aspirin 100 mg and the study is intended to show, if patients given rivaroxaban have fewer blood clots in the brain (stroke) or in other blood vessels.
Study identification
- NCT ID
- NCT02313909
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 7,213 participants
Conditions and interventions
Conditions
Interventions
- Rivaroxaban (Xarelto, BAY59-7939) Drug
- Acetylsalicylic acid (Aspirin, BAY1019036) Drug
- Rivaroxaban-Placebo Other
- Aspirin-Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 23, 2014 (Actual)
- Primary completion
- Feb 15, 2018 (Actual)
- Completion
- Feb 15, 2018 (Actual)
- Last update posted
- Jan 9, 2019
2014 – 2018
United States locations
- U.S. sites
- 38
- U.S. states
- 21
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tucson | Arizona | 85724 | — |
| Not listed | Long Beach | California | 90806 | — |
| Not listed | Stanford | California | 94305-5119 | — |
| Not listed | Torrance | California | 90502 | — |
| Not listed | New Haven | Connecticut | 06520-8064 | — |
| Not listed | Gainesville | Florida | 32611 | — |
| Not listed | Joliet | Illinois | 60435 | — |
| Not listed | Iowa City | Iowa | 52242-1089 | — |
| Not listed | Lexington | Kentucky | 40536 | — |
| Not listed | New Orleans | Louisiana | 70121 | — |
| Not listed | Baltimore | Maryland | 21210 | — |
| Not listed | Boston | Massachusetts | 02111 | — |
| Not listed | Boston | Massachusetts | 02118 | — |
| Not listed | Worcester | Massachusetts | 01655 | — |
| Not listed | Ann Arbor | Michigan | 48109-0330 | — |
| Not listed | Mount Clemens | Michigan | 48043 | — |
| Not listed | New Brunswick | New Jersey | 08901 | — |
| Not listed | Buffalo | New York | 14203 | — |
| Not listed | New York | New York | 10016-4576 | — |
| Not listed | Cincinnati | Ohio | 45219 | — |
| Not listed | Cleveland | Ohio | 44106-2602 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Portland | Oregon | 97225 | — |
| Not listed | Portland | Oregon | 97239-3011 | — |
| Not listed | Erie | Pennsylvania | 16550 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Pittsburgh | Pennsylvania | 15212 | — |
| Not listed | Charleston | South Carolina | 29425 | — |
| Not listed | Columbia | South Carolina | 29203-8004 | — |
| Not listed | Nashville | Tennessee | 37232-5400 | — |
| Not listed | Austin | Texas | 78701 | — |
| Not listed | Dallas | Texas | 75390 | — |
| Not listed | El Paso | Texas | 79905-2709 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Temple | Texas | 76504 | — |
| Not listed | Salt Lake City | Utah | 84312 | — |
| Not listed | Seattle | Washington | 98102 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 416 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02313909, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 9, 2019 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02313909 live on ClinicalTrials.gov.